Role of Zinc Finger Domains of the Transcription Factor Neuron-restrictive Silencer Factor/Repressor Element-1 Silencing Transcription Factor in DNA Binding and Nuclear Localization*

Masahito Shimojo, Jeong-Heon Lee, and Louis B. HershDagger

From the Department of Biochemistry, University of Kentucky, Lexington, Kentucky 40563-0298

Received for publication, December 12, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The transcription factor neuron-restrictive silencer factor/repressor element-1 (RE-1) silencing transcription factor (NRSF/REST) contains nine zinc finger domains and binds to the DNA element, neuron-restrictive silencer element/repressor element-1. REST4, a C-terminally truncated form of NRSF/REST, contains the five N-terminal zinc fingers and binds weakly to DNA yet is transported into the nucleus. To study the contribution of zinc fingers 6-8 to DNA binding, each was mutated. A mutation in zinc finger 6 or 8 had little effect; however, mutation of zinc finger 7 diminished DNA binding. Mutations in any two of these zinc fingers eliminated DNA binding. The contribution of zinc fingers 2-5 to nuclear targeting was studied. Deletion of zinc finger 5 prevented nuclear targeting. Mutations in zinc finger 2, 4, or 5 did not abolish nuclear targeting. However, a zinc finger 3 mutation together with a zinc finger 2 mutation localized to the nuclear envelope. A zinc finger 3 mutation alone or in combination with a zinc finger 4 or 5 mutation produced a punctate nuclear distribution. These results suggest the presence of signals for nuclear targeting, for nuclear entry, and for release from the translocation machinery within zinc fingers 2-5 of REST4.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recent studies have established that one mechanism for the maintenance of the neuronal phenotype is through repression of neuronal gene expression in nonneuronal tissues (1, 2). Thus, a number of neuron-specific proteins including choline acetyltransferase (3), synapsin I (4), SCG10 (5), the type II sodium channel (6), the N-methyl-D-aspartate receptor (7) and neuron-glia cell adhesion molecule (8), to name but a few, contain within their genes a 21-base pair DNA sequence referred to as the neuron-restrictive silencer element (NRSE).1 This element is also called repressor element-1 (RE-1) (1). The transcription factor that binds to NRSE/RE-1 is known as the neuron-restrictive silencer factor (NRSF)/RE-1-silencing transcription factor (REST). It is a 210-kDa glycoprotein containing nine zinc finger domains whose expression appears limited to nonneuronal cell types. NRSF/REST can also act as a silencer of neuron-specific gene expression in undifferentiated neuronal progenitor cells (1, 2). It has been shown that the absence of the NRSE/RE-1 sequence (9) or expression of a dominant negative form of NRSF/REST produces expression of target genes in nonneuronal cells (10). A mouse model in which the NRSF/REST gene was deleted, although embryonic lethal, showed aberrant expression of SCG10 and tubulin beta III in nonneuronal tissues (10).

A number of splice variants of NRSF/REST have been reported (11). Two of these, REST4 and REST5, were found to be expressed at low levels in mature neurons of adult brain (11). These splice variants contain an insertion between zinc finger domains 5 and 6 that leads to truncated proteins containing only five of the nine zinc finger domains found in NRSF/REST. We previously suggested that, at least in PC12 cells, one of these isoforms, REST4, regulates cholinergic gene expression. The mechanism appears to involve formation of hetero-oligomers between REST4 and NRSF/REST, which prevents binding of NRSF/REST to the NRSE/RE-1 sequence (12). To further study the function of NRSF/REST and REST4, we have prepared and studied deletion constructs as well as constructs containing point mutations that cause disruption of the structure of individual Cys2-His2 type zinc finger domains. The results of these studies suggest that proper zinc finger structure is important for DNA binding as well as for nuclear localization.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Deoxyribonucleotides, Dulbecco's modified Eagle's medium, and fetal bovine serum were obtained from Life Technologies, Inc. Oligonucleotide primers were synthesized with a Beckman Oligo1000 DNA synthesizer or purchased from commercial sources. [gamma -32P]ATP was from ICN (Irvine, CA). The BCA protein assay kit was obtained from Pierce. Poly(dI-dC)·poly(dI-dC) was obtained from Amersham Pharmacia Biotech. The ECL Western blotting detection system and HybondTM-P membranes were purchased from Amersham Pharmacia Biotech. Effectene Transfection Reagent and Qiagen plasmid kit were obtained from Qiagen Inc. (Valencia, CA). The pcDNA3 expression vector was obtained from Invitrogen (Carlsbad, CA), while pEGFP and pCMVbeta were obtained from CLONTECH (Palo Alto, CA). All other reagents were from Sigma and were of the highest quality available.

Construction of Plasmids-- Constructs containing green fluorescent protein (GFP) fused to REST4 were generated by subcloning the HindIII-BamHI fragment of corresponding FLAG-REST4 constructs into pEGFP. Mutations were generated by the QuickChangeTM site-directed mutagenesis kit (Stratagene, La Jolla, CA) using NRSF/REST or GFP-REST4 as the DNA template and the following oligonucleotide pairs as primers: 5'-C AAA GGC CCC ATC CGC CGT GAC CGC TGT GGC TAC-3' and 5'-GTA GCC ACA GCG GTC ACG GCG GAT GGG GCC TTT G-3' (for Z2mut), 5'-GAG CGC ATC TAC AAG CGT ATC ATC TGC ACG TAC-3' and 5'-GTA CGT GCA GAT GAT ACG CTT GTA GAT GCG CTC-3' (for Z3mut), 5'-GG AAA GTC TAC ACC CGT AGC AAG TGC AAC TAC-3' and 5'-GTA GTT GCA CTT GCT ACG GGT GTA GAC TTT CC-3' (for Z4mut), 5'-GAA CGC CCG TAT AAA CGG GAA CTT TGT CCT TAC-3' and 5'-GTA AGG ACA AAG TTC CCG TTT ATA CGG GCG TTC-3' (for Z5mut), 5'-GAG AAG CCA TTT AAA CGG GAT GAG TGC AAT TAT G-3' and 5'-C ATA ATT GCA CTC ATC CCG TTT AAA TGG CTT CTC-3' (for Z6mut), 5'-CCT AAA CCT CTT AAT CGT CCG CAC TGT GAC TAC-3' and 5'-GTA GTC ACA GTG CGG ACG ATT AAG AGG TTT AGG-3' (for Z7mut), 5'-CCA CGG CAG TTC AAC CGT CCC GTG TGT GAC TAC-3' and 5'-GTA GTC ACA CAC GGG ACG GTT GAA CTG CCG TGG-3' (for Z8mut). Underlined nucleotides denote changes introduced (Cys to Arg). The identities of the plasmid constructs were verified by the cycle sequencing method using Sequenase (U.S. Biochemical Corp.). For the preparation of beta -galactosidase fused to zinc finger domains 2-5 (Z2,3,4,5) or to zinc finger domains 2-4 (Z2,3,4), appropriate fragments were amplified by the polymerase chain reaction from an NRSF/REST template. Primers used were as follows: Z2S, 5'-GAT GGA CTA CAA GGA CGA CGA CGA CAA GCC CAT CCG CTG TGA CCG CTG-3'; Z4AS, 5'-GGG CGT TCT CCT GTG TGA GT-3'; Z5AS, TCA CCT GAA TGA GTC CGC AT-3'. The amplified products were cloned into the SmaI site of pBSSK. A HindIII/BamHI fragment was cloned into beta -galactosidase-pcDNA3. The latter was created by inserting the beta -galactosidase gene from pCMVbeta (CLONTECH) into the NotI site of pcDNA3. The preparation of deletion mutants was as described in Lee et al. (13).

Cell Culture and Transfection-- HEK293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (Life Technologies, Inc.). These cells were maintained at 37 °C in a humidified atmosphere of 10% CO2. Transfections were performed with the use of the Effectene Transfection Reagent (Qiagen) according to the manufacturer's instructions.

Detection of GFP and beta -Galactosidase-- NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum at 37 °C in 5% CO2. For transfection with GFP or beta -galactosidase-containing constructs, cells were plated on 100-mm2 glass coverslips at a density of 105 cells/coverslip on the day before transfection. The cells were transfected with GFP-tagged or beta -galactosidase-tagged expression constructs using the Effectene Transfection Reagent. For visualizing, GFP cells were grown for 24 h and then fixed in dry ice-methanol for 5 min. Cells were then washed three times in PBS, counterstained with 4',6-diamidino-2-phenylindole in PBS (1:5000 dilution) for 5 min and then washed with PBS. Coverslips were mounted in Vectashield H-1000 (Vector Laboratories, Inc.). GFP was observed using a Nikon E600 epifluorescent microscope (Melville, NY). For beta -galactosidase staining, cells were fixed in 1% glutaraldehyde for 5 min; washed three times in PBS; soaked in 100 mM sodium phosphate, pH 7.5, 10 mM KCl, 1 mM MgCl2, 3 mM K4(Fe(CN)6), 3 mM K3(Fe(CN)6), 0.1% Triton X-100, and 1 mM X-gal at 37 °C for 30 min; and then washed with PBS.

Electrophoretic Mobility Shift Assays (EMSA)-- Nuclear extracts were prepared from cells as described previously (12). The probe for EMSA was made by polymerase chain reaction using the human vesicular acetylcholine transporter/choline acetyltransferase NRSE/RE-1 as a template (see Fig. 2A). DNA fragments were end-labeled with [gamma -32P]ATP using T4 polynucleotide kinase. For binding, 10 µg of nuclear protein was preincubated on ice, with or without a 100-fold excess of unlabeled competitor DNA, for 10 min in 20 µl of 20 mM HEPES (pH 7.6), 0.1% Nonidet P-40, 10% glycerol, 1 mM dithiothreitol, 2.5 mM MgCl2, 250 mM KCl, and 2 µg of poly(dI-dC)·poly(dI-dC). Labeled oligonucleotide (100 fmol) was mixed with nuclear protein, and the mixture was incubated for 10 min at 25 °C. For supershift assays, 10 µg of nuclear protein was preincubated on ice with or without a monoclonal antibody to NRSF/REST (12C11-1) for 30 min before adding the labeled probe. The reaction mixture was loaded onto a 4% nondenaturing polyacrylamide gel with 0.25× TBE buffer and electrophoresed for 60 min at 120 V.

Western Blot Analysis-- Nuclear extracts (10 µg) were solubilized in Laemmli sample buffer. After separation on a reducing SDS-polyacrylamide gel, proteins were transferred onto HybondTM-P membrane as described previously (12). The membrane was then incubated with anti-NRSF/REST (12C11-1), anti-FLAG, or anti-Myc monoclonal antibody followed by horseradish peroxidase-labeled goat anti-mouse antiserum, and visualized using the ECL detection kit per the manufacturer's instructions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

As illustrated in Fig. 1, NRSF/REST is a transcription factor containing nine zinc finger domains; the first of these is near the N terminus and is followed by a cluster of seven zinc finger domains, with the last zinc finger domain being near the C terminus of the molecule. REST4, which is a truncated version of NRSF/REST containing only zinc finger domains 1-5, binds weakly to the NRSF/REST target sequence NRSE/RE-1 (13). This finding as well as other studies (1) suggests that zinc finger domains 2-5 are required for DNA binding, while zinc finger domains 6-8 appear to contribute significantly to the strength of the binding interaction (13). To study further the contributions of zinc finger domains 6-8, NRSF/REST constructs with combinations of point mutations in these zinc finger domains were constructed, Fig. 1. Each zinc finger structure was disrupted by introducing a point mutation where the amino acid Cys was converted to Arg in the zinc finger domain. This mutation has been shown to disrupt the structure of Cys2-His2 type zinc finger domains (14). Each construct was transfected into HEK293 cells, and nuclear extracts were prepared and used for EMSA with a probe containing the human vesicular acetylcholine transporter/choline acetyltransferase NRSE/RE-1 sequence (Fig. 2A). As can be seen in Fig. 2B, the EMSA shows that the binding of NRSF/REST with mutations in zinc finger domains 6, 7, and 8 (Z6,7,8mut) diminished the gel mobility shift to levels undetectable at the sensitivity of these assays. Diminished binding was also seen in double mutants containing point mutations in zinc finger domains 6 plus 7 (Z6,7mut), 7 plus 8 (Z7,8mut), and 6 plus 8 (Z6,8mut). The presence of a point mutation in zinc finger domain 6 alone (Z6mut) or zinc finger domain 8 alone (Z8mut) had little or no effect on DNA binding; however, a point mutation in zinc finger domain 7 alone (Z7mut) greatly diminished DNA binding. As shown in Fig. 2C, the expression level of each construct was nearly the same as confirmed by Western blot analysis, and if anything the construct with the point mutation in zinc finger domain 7 was expressed at the highest levels. As shown in Fig. 2D, the electrophoretic mobility band was supershifted with an anti-NRSF monoclonal antibody but not by an irrelevant monoclonal antibody, confirming that the electrophoretic mobility band contained NRSF/REST. Taken together, these results suggest that in addition to zinc fingers 2-5, two adjacent zinc fingers (zinc fingers 6 plus 7 or 7 plus 8) are required for maximal DNA binding.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic diagram of NRSF/REST constructs with point mutations in zinc finger domains. NRSF/REST is schematically represented, with striped boxes, indicating zinc finger domains and filled boxes indicating zinc finger domains with a Cys to Arg point mutation.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Electrophoretic mobility shift assays of NRSF/REST constructs with point mutations in zinc finger domains. A, the probe used for EMSA corresponds to the human NRSE/RE-1 sequence upstream of the vesicular acetylcholine transporter and choline acetyltransferase genes in the human cholinergic gene locus. The 21-base pair NRSE/RE-1 sequence is underlined. B, EMSA of nuclear extracts (10 µg) from HEK293 cells containing NRSF/REST with point mutations. C, immunoblot analysis of each nuclear extract with anti-NRSF monoclonal antibody. D, supershifting of NRSE/RE-1 gel shift band. Nuclear extracts with NRSF (+NRSF) or without NRSF (-NRSF) from HEK293 cells were applied to EMSA. For the supershift assay, nuclear extracts were preincubated for 30 min on ice before adding the probe with anti-NRSF monoclonal antibody or control monoclonal antibody against mouse choline acetyltransferase where indicated.

Although the above studies demonstrate the importance of zinc finger domains 6-8 in NRSF/REST binding to DNA, previous studies have shown that the neuron-specific isoform REST4, which contains only zinc finger domains 1-5, is targeted to the nucleus (15). This was a bit surprising, since it had previously been proposed that a nuclear localization domain of NRSF/REST resides in the C-terminal part of the molecule (1, 16), and this signal is clearly absent from REST4. We first tested the effect of deleting the N-terminal region of REST4, which is known to bind the transcriptional repressor mSin3 (16-18), and then a larger fragment of the N-terminal region, which contains the first zinc finger domain. Fig. 3A shows a schematic representation of these and other truncated forms of REST4 that were studied, each containing an N-terminal FLAG epitope for ease of identification. These constructs were transiently expressed in HEK293 cells followed by fractionating the cells into nuclear and cytosolic extracts and locating the REST4 mutant by Western blot analysis with an anti-FLAG antibody. Western blots employing an anti-Myc antibody were used as positive controls to detect endogenous Myc protein in the nucleus. As shown in Fig. 3B, cell fractionation analysis showed that deletion of the mSin3 binding region (Delta N152) or this region plus the first zinc finger domain (Delta N209) did not affect nuclear targeting. On the other hand, constructs containing deletions of zinc finger domains 3-5 (Delta C89), zinc finger domains 2-5 (Delta C151), or zinc finger domains 1-5 (Delta C173) were detected in the cytosol but not in the nucleus. These results suggest that zinc finger domains 2-5 are required for nuclear targeting of REST4 and presumably NRSF/REST.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 3.   Cellular localization of truncated NRSF/REST mutants in HEK293 cells. A, schematic representation of N- or C-terminally truncated mutants of REST4. A FLAG tag was fused to the N terminus of all constructs so that they could be detected with anti-FLAG antibody. Striped boxes represent zinc finger domains. B, Western blot analysis of nuclear extracts and the cytosolic fraction from transfected HEK293 cells. Each truncated NRSF/REST mutant was expressed in HEK293 cells, and nuclear (N) and cytosolic (C) extracts were prepared. Each extract (10 µg) was subjected to immunoblot analysis with anti-FLAG or anti-Myc antibodies, respectively. Myc was used as an endogenous nuclear protein marker.

To demonstrate the importance of zinc finger domains 2-5 in nuclear targeting in vivo, GFP was fused to REST4; to REST1 (11), which is a natural isoform lacking zinc finger domain 5; and to a C-terminally truncated mutant lacking zinc finger domains 3-5 (Delta C89). These constructs were transiently expressed in NIH3T3 cells, and their localization was determined by GFP fluorescence microscopy. As shown in Fig. 4, although REST4 was localized in the nucleus, the deletion of zinc finger domain 5 was sufficient to prevent nuclear localization. We next confirmed whether zinc finger domains 2-5 would localize a larger protein to the nucleus by fusing this region to beta -galactosidase. As shown in Fig. 5, the attachment of zinc finger domains 2-5 to the N terminus of beta -galactosidase (Z2,3,4,5) conferred nuclear localization in NIH3T3 cells as judged by histochemical staining of the cells with X-gal. Neither beta -galactosidase alone nor a construct containing zinc finger domains 2-4 (Z2,3,4) fused to beta -galactosidase was localized to the nucleus.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Localization of GFP-truncated REST4 mutants in NIH3T3 cells. A, schematic of constructs of GFP-truncated REST4 mutants. Each construct was fused C-terminally to GFP. Striped boxes indicate zinc finger domains. B, fluorescence microscopy of GFP-truncated REST4 mutants. NIH3T3 cells were transfected with expression constructs encoding the GFP-truncated REST4 mutants shown above. After fixation, cells were examined by fluorescence microscopy. Green and blue staining represent GFP and nuclear (4',6-diamidino-2-phenylindole) staining, respectively.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 5.   Cellular localization of beta -galactosidase-REST4 zinc finger domain chimeras. A, schematic representation of beta -galactosidase-REST4 zinc finger domain chimeras. B, histochemical staining of NIH3T3 cells transfected with the beta -galactosidase-REST4 zinc finger domain chimeras shown above.

To further dissect the importance of zinc finger domains 2-5 for nuclear localization of REST4, a series of constructs were generated that contained a point mutation that disrupted the conformation of the zinc finger domain. Constructs containing one, two, three, or four of these point mutations fused to GFP were prepared and are schematically represented in Fig. 6A. As shown in Fig. 6B, a single point mutation in any one zinc finger domain permitted nuclear targeting. However, as noted below, the zinc finger domain 3 mutant, although localized to the nucleus, showed an abnormal staining pattern. Similarly, combinations of double mutants involving zinc finger domains 2 and 4 (Z2,4mut), zinc finger domains 2 and 5 (Z2,5mut), and zinc finger domains 4 and 5 (Z4,5mut) all showed normal nuclear localization, as did the triple mutant involving zinc finger domains 2, 4, and 5 (Z2,4,5mut). However, all constructs containing a mutation in zinc finger domain 3 (Z3mut, Z3,4mut, Z3,5mut, Z2,3,5mut, and Z3,4,5mut), although associated with the nucleus, appeared abnormal. The zinc finger domain 3 single mutant as well as the zinc finger domain 3 plus 4 double mutant and the zinc finger domain 3 plus 5 double mutant showed nuclear staining that was punctate rather than uniform across the nucleus. A more dramatic pattern was seen with a zinc finger domain 3 mutant in combination with a zinc finger domain 2 mutation. Mutant Z2,3mut, Z2,3,4mut, or Z2,3,5mut or the construct containing mutations in all four zinc finger domains (Z2,3,4,5mut) exhibited GFP fluorescence that appeared on the surface of the nucleus rather than inside the nucleus.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Cellular localization of GFP-REST4 constructs containing zinc finger mutations. A, schematic representation of GFP-REST4 constructs containing point mutations in zinc finger domains. The striped boxes represent zinc finger domains, while the filled boxes represent zinc finger domains with a Cys to Arg point mutation. B, fluorescence microscopy of NIH3T3 cells expressing GFP-REST4 point mutants. Green and blue staining represent GFP and nuclear (4',6-diamidino-2-phenylindole) staining, respectively.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NRSF/REST is a transcription factor that contains nine Cys2-His2 type zinc finger domains. It has previously been suggested that the zinc finger domains of NRSF/REST contribute to its binding to the DNA sequence known as NRSE/RE-1. REST4, which is a C-terminally truncated neuron-specific isoform of NRSF/REST, contains only the first five of the nine Cys2-His2 type zinc finger domains. Although the physiological function of REST4 remains unclear, the binding affinity of REST4 to NRSE/RE-1 is lowered dramatically to ~<FR><NU>1</NU><DE>10</DE></FR> to <FR><NU>1</NU><DE>20</DE></FR> of NRSF/REST (13). These data suggest that other zinc finger domains, notably zinc finger domains 6-8, contribute to DNA binding (13). To study the contributions of these zinc finger domains to DNA binding, a point mutation was introduced into each in which the amino acid Cys was changed to Arg. It has previously been established that this mutation disrupts the conformation and function of Cys2-His2 type zinc finger domains (14). As expected introducing this mutation into zinc finger domains 6-8 together (Z6,7,8mut) decreased DNA binding to an undetectable level. Binding of the mutant could only be detected by adding higher concentrations of the nuclear extract. Similarly, combinations of mutations in any two of the three zinc finger domains (Z6,7mut, Z7,8mut, or Z6,8mut) greatly diminished binding to the NRSE/RE-1 probe. Single mutations in zinc finger domains 6 or 8 had little or no effect on DNA binding; however, mutation of zinc finger domain 7 alone greatly reduced DNA binding. These data suggest that all three zinc finger domains can contribute to DNA binding; however, two adjacent zinc fingers, either zinc finger 6 plus 7 or zinc finger 7 plus 8, are required to produce maximal DNA binding.

Although zinc finger domains 6-8 contribute to DNA binding, REST4, which lacks these domains as well as zinc finger domain 9, appears to be efficiently targeted to the nucleus (Figs. 3 and 4). REST4 also lacks the putative nuclear localization signal found in the C-terminal region of NRSF/REST (1, 16). Therefore, either there are two nuclear localization signals in NRSF/REST, or the nuclear localization signal found in REST4 is the functional one. Deletion mutagenesis previously indicated that the nuclear targeting signal of REST4 resides within the C-terminal region containing zinc finger domains 2-5 (15), and this was confirmed in this study by both cell fractionation and in vivo fluorescence measurements using GFP-REST4 constructs. We further demonstrated that zinc finger domains 2-5, but not 2-4, could target beta -galactosidase to the nucleus. In addition, REST1, which is similar to REST4, but lacks zinc finger domain 5, was not targeted to the nucleus. Although these results would suggest that zinc finger 5 is required for nuclear localization, a point mutation in zinc finger 5 did not prevent nuclear localization. We can conclude that there is a nuclear targeting signal, other than the zinc finger domain, located within amino acids 296-328, which comprise the region preceding and through zinc finger 5. There are several basic residues in this region that could participate in a nuclear targeting signal. Alternatively, deletion of amino acids 296-328 changes the structure of the protein such that a critical conformation needed for nuclear targeting is disrupted.

To determine whether the zinc finger domain structures are important for nuclear targeting, REST4 with combinations of Cys to Arg point mutations in the zinc finger domains was constructed and fused C-terminally to GFP. None of the combinations of point mutations in zinc finger domains 2-5 changed the localization of REST4 from nuclear to cytoplasmic; thus, a functional structure of the zinc finger domains is not required to target REST4 to the nucleus. On the other hand, disruption of zinc finger domain 3 alone or in combination with other zinc finger domain mutations produced abnormal nuclear localization. A punctate staining of the nucleus was seen with the zinc finger domain 3 single mutant as well as with the zinc finger domain 3 and 4 and zinc finger domain 3 and 5 double mutants. These GFP-REST4 constructs appeared to enter the nucleus but were not dispersed uniformly throughout the nucleus. A different pattern was observed with the zinc finger domain 3 mutant in combination with a zinc finger domain 2 mutation. In these cases, the GFP-REST4 constructs appeared to localize to the edge of the nucleus, as if they were attached to the nuclear envelope.

It has been suggested that zinc finger domains not only function in DNA recognition (19), but also can be involved in protein-protein interactions (20, 21) and in determining subcellular localization (22, 23). Nuclear protein import including that of transcription factors such as NRSF/REST or REST4 is a key control point in regulating gene expression. Nuclear localization signal-mediated transport into the nucleus probably involves at least two processes: targeting to the nucleus and translocation with the nuclear pore complexes. The first step is suggested to be an energy-independent recognition of the targeting signal of the transport substrate and subsequent docking at the nuclear pore complexes. The second step is energy-dependent and involves translocation through the pore and into the nucleus (24, 25). Taken together, our results suggest the presence of three signals in REST4 that contribute to its nuclear localization. One signal, which does not require a functional zinc finger domain, is necessary to target REST4 to the nucleus. This signal lies within amino acids 296-328, since REST1 and the REST4 zinc finger 5 deletion mutant, both of which lack these amino acids, are not targeted to the nucleus. A second signal appears to be required to translocate REST4 across the nuclear membrane, and this signal appears to require both zinc finger domain 2 and zinc finger domain 3. Third, a signal residing in zinc finger domain 3 releases REST4 from the translocation machinery so that it can disperse throughout the nucleus. A less likely but alternative explanation is that the mutation in zinc finger domain 3 introduces a cryptic signal, which causes association of REST4 with nuclear membranes.

    FOOTNOTES

* This work was supported in part by NIA, National Institutes of Health, Grant AG05893.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Biochemistry, University of Kentucky, Chandler Medical Center, 800 Rose St., Lexington, KY 40536-0298. Tel.: 859-323-5549; Fax: 859-323-1727; E-mail: lhersh@pop.uky.edu.

Published, JBC Papers in Press, January 5, 2001, DOI 10.1074/jbc.M011193200

    ABBREVIATIONS

The abbreviations used are: NRSE, neuron-restrictive silencer element; RE-1, repressor element-1; NRSF, neuron-restrictive silencer factor; REST, RE-1 silencing transcription factor; X-gal, 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside; GFP, green fluorescent protein; PBS, phosphate-buffered saline; EMSA, electrophoretic mobility shift assay(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Chong, J. A., Tapia-Ramirez, J., Kim, S., Toledo-Aral, J. J., Zheng, Y., Boutros, M. C., Altshuller, Y. M., Frohman, M. A., Kraner, S. D., and Mandel, G. (1995) Cell 80, 949-957[Medline] [Order article via Infotrieve]
2. Schoenherr, C. J., and Anderson, D. J. (1995) Science 267, 1360-1363[Medline] [Order article via Infotrieve]
3. Lonnerberg, P., Schoenherr, C. J., Anderson, D. J., and Ibanez, C. F. (1996) J. Biol. Chem. 271, 33358-33365[Abstract/Free Full Text]
4. Li, L., Suzuki, T., Mori, N., and Greengard, P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1460-1464[Abstract]
5. Mori, N., Schoenherr, C. J., Vandenbergh, D. J., and Anderson, D. J. (1992) Neuron 9, 45-54[Medline] [Order article via Infotrieve]
6. Kraner, S. D., Chong, J. A., Tsay, H. J., and Mandel, G. (1992) Neuron 9, 37-44[Medline] [Order article via Infotrieve]
7. Bai, G., Norton, D. D., Prenger, M. S., and Kusiak, J. W. (1998) J. Biol. Chem. 273, 1086-1091[Abstract/Free Full Text]
8. Kallunki, P., Jenkinson, S., Edelman, G. M., and Jones, F. S. (1995) J. Biol. Chem. 270, 21291-21298[Abstract/Free Full Text]
9. Kallunki, P., Edelman, G. M., and Jones, F. S. (1997) J. Cell Biol 138, 1343-1354[Abstract/Free Full Text]
10. Chen, Z.-F., Paquette, A. J., and Anderson, D. J. (1998) Nat. Genet. 20, 136-142[CrossRef][Medline] [Order article via Infotrieve]
11. Palm, K., Belluardo, N., Metsis, M., and Timmusk, T. (1998) J. Neurosci. 18, 1280-1296[Abstract/Free Full Text]
12. Shimojo, M., Paquette, A. J., Anderson, D. J., and Hersh, L. B. (1999) Mol. Cell. Biol. 19, 6788-6795[Abstract/Free Full Text]
13. Lee, J.-H., Shimojo, M., Chai, Y.-G., and Hersh, L. B. (2000) Brain Res. Mol. Brain Res. 80, 88-98[Medline] [Order article via Infotrieve]
14. Tapia-Ramirez, J., Eggen, B. J., Peral-Rubio, M. J., Toledo-Aral, J. J., and Mandel, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1177-1182[Abstract/Free Full Text]
15. Lee, J.-H., Chai, Y-G., and Hersh, L. B. (2000) J. Mol. Neurosci. 80, 88-98
16. Grimes, J. A., Nielsen, S. J., Battaglioli, E., Miska, E. A., Speh, J. C., Berry, D. L., Atouf, F., Holdener, B. C., Mandel, G., and Kouzarides, T. (2000) J. Biol. Chem. 31, 9461-9467[CrossRef]
17. Huang, Y., Myers, S. J., and Dingledine, R. (1999) Nat. Neurosci. 2, 867-872[CrossRef][Medline] [Order article via Infotrieve]
18. Naruse, Y., Aoki, T., Kojima, T., and Mori, N. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13691-13696[Abstract/Free Full Text]
19. Wolfe, S. A., Nekludova, L., and Pabo, C. O. (2000) Annu. Rev. Biophys. Biomol. Struct. 3, 183-212
20. Lee, J. S., Galvin, K. M., and Shi, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6145-6149[Abstract]
21. Milne, C. A., and Segall, J. (1993) J. Biol. Chem. 268, 11364-11371[Abstract/Free Full Text]
22. Bruening, W., Moffett, P., Chia, S., Heinrich, G., and Pelletier, J. (1996) FEBS Lett. 393, 41-47[CrossRef][Medline] [Order article via Infotrieve]
23. Matheny, C., Day, M. L., and Milbrandt, J. (1994) J. Biol. Chem. 269, 8176-8181[Abstract/Free Full Text]
24. Newmeyer, D. D., and Forbes, D. J. (1988) Cell 52, 641-653[Medline] [Order article via Infotrieve]
25. Richardson, W. D., Mills, A. D., Dilworth, S. M., Laskey, R. A., and Dingwall, C. (1988) Cell 52, 655-664[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.